Live Breaking News & Updates on Arcutis Biotherapeutics Company Profile|Page 4

Stay updated with breaking news from Arcutis biotherapeutics company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $43.43 Consensus Price Target from Brokerages

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have received a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price […] ....

Arcutis Biotherapeutics , Arcutis Biotherapeutics Company Profile , Needham Company , Wadegw Inc , Alphacentric Advisors , Prelude Capital Management , Cantor Fitzgerald , Arcutis Biotherapeutics Inc , Connor Clark Lunn Investment Management Ltd , Hennion Walsh Asset Management Inc , Goldman Sachs Group , Get Free Report , Lunn Investment Management , Centric Advisors , Capital Management , Walsh Asset Management , Get Free , Nasdaq Arqt ,

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued a report […] ....

Arcutis Biotherapeutics , Connor Clark Lunn Investment Management Ltd , Needham Company , Arcutis Biotherapeutics Inc , Hennion Walsh Asset Management Inc , Alphacentric Advisors , Prelude Capital Management , Arcutis Biotherapeutics Company Profile , Cantor Fitzgerald , Wadegw Inc , Get Free Report , Lunn Investment Management , Centric Advisors , Capital Management , Walsh Asset Management , Get Free , Nasdaq Arqt ,

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Rating of "Buy" by Analysts

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Rating of "Buy" by Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Arcutis Biotherapeutics , Jennison Associates , Cantor Fitzgerald , Arcutis Biotherapeutics Inc , Blackrock Inc , Arcutis Biotherapeutics Company Profile , Get Free Report , Street Corp , Capital Management , Get Free ,

Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Cut to $50.00 by Analysts at TD Cowen

Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its target price reduced by TD Cowen from $65.00 to $50.00 in a research note issued to investors on Wednesday, Benzinga reports. TD Cowen currently has an outperform rating on the stock. A number of other brokerages also recently issued reports on ARQT. 500.com reaffirmed a reiterates rating […] ....

Arcutis Biotherapeutics , Morgan Stanley , Jpmorgan Chase Co , Metlife Investment Management , Dimensional Fund Advisors , Arcutis Biotherapeutics Company Profile , Needham Company , Arcutis Biotherapeutics Inc , Vanguard Group Inc , Swiss National Bank , Free Report , Get Free Report , National Bank , Life Investment Management , Fund Advisors , Vanguard Group ,

Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 5.1%

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report)’s stock price fell 5.1% during mid-day trading on Monday . The company traded as low as $9.95 and last traded at $9.95. 147,462 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 1,102,637 shares. The stock had previously closed at […] ....

Hong Kong , Arcutis Biotherapeutics , Zurcher Kantonalbank Zurich Cantonalbank , Arcutis Biotherapeutics Inc , Arcutis Biotherapeutics Company Profile , First Republic Investment Management Inc , Needham Company , Ballentine Partners , Hong Kong Ltd , Get Free Report , Kong Ltd , Kantonalbank Zurich Cantonalbank , Republic Investment Management , Nasdaq Arqt ,